Long COVID Care Moves to the Frontline as Doctors Get a Practical Playbook

Years after the World Health Organization declared an end to the global health emergency, Long COVID remains one of medicine’s most stubborn puzzles, and most of its patients are not being seen in specialist clinics. They are sitting in primary care exam rooms, describing exhaustion, racing hearts, and a mental fog that no laboratory test can explain. A new narrative review published in the Journal of General Internal Medicine by Anita Chopra of the University of Washington, Hector F. Bonilla of Stanford University, and Abby L. Cheng of Washington University in St. Louis offers clinicians a pragmatic framework for recognizing and managing the condition, built explicitly for the realities of a fifteen-minute visit rather than the leisurely pace of a research center.

The scale of the problem justifies the effort. The most recent estimates cited by the authors suggest that roughly six percent of United States adults and half a percent of children and adolescents are still living with new or persistently worsened symptoms that began shortly after an acute SARS-CoV-2 infection. For clinical purposes, the authors define Long COVID as new or worsened symptoms developing after confirmed or suspected infection and persisting for more than three months, a deliberately broad formulation that sidesteps the stricter laboratory-confirmation requirements of research definitions. The dominant symptoms cluster around fatigue, post-exertional malaise, cognitive impairment often called brain fog, and orthostatic intolerance, the lightheadedness and palpitations that appear or worsen when a patient stands upright.

What makes the review distinctive is its use of clinical vignettes that mirror how patients actually describe their lives. In one case, a 32-year-old woman with a history of anxiety reports four months of fatigue that is qualitatively different from anything she has felt before. After minimal activity, she describes crashing, as though wearing a lead coat, with profound exhaustion and difficulty thinking that can persist for hours to days. Even preparing meals or answering emails has become a hurdle, and she has cut back her work hours. Her symptoms began about a month after a mild COVID-19 infection, a temporal link that might easily be missed if a clinician never asks about preceding illness.

A second vignette captures the dysautonomia pattern: a previously athletic 19-year-old develops palpitations, lightheadedness, and near-fainting on standing, symptoms that improve when she lies down. She recalls an upper respiratory illness two weeks before onset, and although she never tested herself, multiple family members had confirmed COVID-19 at the time. A third describes a 45-year-old aerospace engineer whose forgetfulness, word-finding difficulty, and slowed processing speed have cost him deadlines at work, all despite a normal basic laboratory evaluation. Together, the cases illustrate the review’s central message: Long COVID frequently announces itself through recognizable symptom clusters, and related conditions such as myalgic encephalomyelitis/chronic fatigue syndrome and postural orthostatic tachycardia syndrome often ride alongside it.

Beneath the clinical patterns, the authors propose a three-part conceptual framework for what SARS-CoV-2 actually leaves behind. The first category is a hit-and-run phenomenon, in which acute infection causes direct end-organ tissue injury with lasting consequences, such as pulmonary fibrosis or vascular events. The second is a stressor effect, in which the infection reduces physiological reserve and unmasks or accelerates chronic diseases like diabetes, hypertension, or rheumatoid arthritis in the following weeks and months. The third and most scientifically contested category is ongoing biological dysregulation, encompassing persistent viral reservoirs, immune dysregulation, gut dysbiosis, mitochondrial dysfunction, and microvascular clotting, processes repeatedly identified in basic science studies but largely invisible to current clinical diagnostic tools. Management of the first two categories follows standard practice, the authors note, while the third currently rests on rehabilitation and supportive care.

Diagnostically, the review resists exotic testing. Because no clinically available biomarker can confirm or exclude Long COVID, and severe symptoms can coexist with entirely normal conventional results, the workup serves mainly to rule out competing diagnoses and addressable sequelae. The authors recommend a focused physical examination guided by the patient’s symptoms, with particular attention to orthostatic vital signs, which are often skipped and frequently abnormal in this population. Targeted laboratory and imaging studies, including complete blood count, metabolic panel, thyroid function, and inflammatory markers, follow the same logic a primary care clinician would apply to any undifferentiated complaint. A validated ten-item questionnaire for post-exertional malaise, the DSQ-PEM, can help document a symptom that patients often struggle to articulate.

On treatment, the message is sobering but constructive: there is no cure, and no FDA-approved medication, yet validation and education alone can meaningfully improve quality of life. The authors emphasize that mental health conditions are not the cause of Long COVID, but the illness frequently produces new or worsened depression and anxiety, partly because patients do not feel believed by clinicians or loved ones. Nonpharmacologic strategies form the backbone of care. Activity pacing, energy conservation, and task modification, such as spreading grocery shopping and meal preparation across separate days or using a scooter and a seated chopping station, help patients live within their energy envelope. Referral to therapists experienced with chronic fatiguing illnesses, typically in neurorehabilitation rather than orthopedic settings, can be transformative: physical therapy for fatigue and activity intolerance, occupational therapy for self-care and job demands, and speech therapy for attention, memory, and breathing discomfort despite normal pulmonary tests.

One warning stands out with unusual force. While some patients tolerate gradual, supervised exercise progression, graded exertion must be approached with extreme caution in patients with post-exertional malaise. The authors cite evidence that even seemingly minor overexertion can trigger delayed symptom flares and has been associated with amyloid deposition, reduced mitochondrial enzyme activity, and signs of severe skeletal muscle damage in affected patients. For those with orthostatic intolerance, simpler measures carry real benefit: increasing daily fluid intake to 2.5 to 3.5 liters and sodium to 2.8 to 4 grams, equivalent to 7 to 10 grams of salt, alongside compression garments such as waist-high stockings or an abdominal binder, provided no contraindications exist.

Pharmacologic management remains symptom-based, borrowing indications from other contexts: beta blockers or ivabradine for POTS, stimulants for attention-dominant brain fog, gabapentinoids for neuropathic pain, and SSRIs for new or worsened mood symptoms. Two off-label options receive special mention. Low-dose naltrexone, an opioid receptor blocker, has been associated in some patients with improved pain, fatigue, and cognition, and a 2026 systematic review and meta-analysis examined the evidence base. Patients with suspected mast cell activation syndrome triggered by Long COVID sometimes report relief from combined H1 and H2 antihistamines. The authors also address the longer arc of illness: symptoms persist beyond one year in roughly a quarter of patients and beyond two years in about ten percent, making documentation of functional impact, workplace accommodation letters, and disability paperwork an essential, billable-worthy part of primary care.

Perhaps the most practical contribution is a set of principles for delivering all of this within a standard visit. The authors advise screening for preceding illness and symptom duration in the history, asking which symptom is most bothersome right now, and tackling only one or two symptoms per visit while leveraging longitudinal follow-up. Medication trials should be stepwise, one intervention at a time, starting low and titrating slowly, with de-prescribing of drugs that may worsen fatigue or cognition. Written after-visit summaries matter disproportionately for patients with cognitive symptoms, and telehealth or first-appointment scheduling can spare fatigued patients the exertion of a waiting room. On prevention, the review is equally concrete: vaccination shows a dose-dependent reduction in Long COVID risk, early outpatient antivirals offer modest protection, with nirmatrelvir/ritonavir associated with a 26 percent relative risk reduction, molnupiravir 14 percent, and ensitrelvir 45 percent, while metformin was linked to a 41 percent reduction in incidence in a randomized trial. Indoor air filtration, N95 or KN95 masking, and isolation during infectivity round out the defensive toolkit. Until reliable biomarkers and curative therapies arrive, the authors argue, the frontline of Long COVID medicine will remain the primary care office, and clinicians equipped with a structured approach can already change what the illness means for the patients living with it.

Subject of Research: Clinical evaluation and management of Long COVID in primary care

Article Title: Long COVID in Primary Care: A Practical Approach to Evaluation and Management

Article References: Chopra, A., Bonilla, H. F., & Cheng, A. L. (2026). Long COVID in Primary Care: A Practical Approach to Evaluation and Management. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10901-w

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10901-w

Keywords: Long COVID, primary care, SARS-CoV-2, post-exertional malaise, dysautonomia, POTS, brain fog, ME/CFS, diagnosis, rehabilitation, antivirals, prevention